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Cholesterol Lowering, Cardiovascular Diseases,
and the Rosuvastatin-JUPITER Controversy
A Critical Reappraisal
Michel de Lorgeril, MD; Patricia Salen, BSc; John Abramson, MD; Sylvie Dodin, MD; Tomohito Hamazaki, PhD;
Willy Kostucki, MD; Harumi Okuyama, PhD; Bruno Pavy, MD; Mikael Rabaeus, MD
Background:Among the recently reported cholesterol-
lowering drug trials, the JUPITER (Justification for the
Use of Statins in Primary Prevention) trial is unique: it
reports a substantial decrease in the risk of cardiovascu-
lar diseases among patients without coronary heart dis-
ease and with normal or low cholesterol levels.
Methods: Careful review of both results and methods
used in the trial and comparison with expected data.
Results: The trial was flawed. It was discontinued (ac-
cording to prespecified rules) after fewer than 2 years of
follow-up, with no differences between the 2 groups on
themost objective criteria. Clinical data showed amajor
discrepancy between significant reduction of nonfatal
stroke and myocardial infarction but no effect on mor-
tality from stroke and myocardial infarction. Cardiovas-
cular mortality was surprisingly low compared with total
mortality—between 5% and 18%—whereas the expected
rate would have been close to 40%. Finally, there was a
very lowcase-fatality rateofmyocardial infarction, far from
the expected number of close to 50%. The possibility that
bias entered the trial is particularly concerning because of
the strong commercial interest in the study.
Conclusion: The results of the trial do not support the
use of statin treatment for primary prevention of cardio-
vascular diseases and raise troubling questions concern-
ing the role of commercial sponsors.
Arch Intern Med. 2010;170(12):1032-1036
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with or without coronary
heart disease (CHD) have been consis-
tently negative.1-9 However, there is one
exception, the JUPITER (Justification for
the Use of Statins in Primary Prevention)
trial,10which showed—in primary preven-
tion—a striking decrease in CHD compli-
cations. The JUPITER trial rapidly pro-
voked controversy11-13 regarding both the
results and the methods used in the trial.
Although enthusiastic comments have
been published,14-17 and the results have
undoubtedly propelled many healthy per-
sonswithoutelevatedcholesterol levelsonto
long-term statin treatment, the clinical rel-
evanceof the JUPITERtrial remains inques-
tion. To understand the rosuvastatin-
JUPITER controversy, we critically review
several significant issues of that study.
The JUPITER trial tested the effects of
rosuvastatin therapy (20 mg/d) in pa-
tients without cardiovascular history or
established CHD and with normal or low
cholesterol levels but relatively high lev-
els of C-reactive protein, a fluctuating
biologicmarker of inflammation.18The au-
thors reported a 50% reduction in low-
density lipoprotein cholesterol levels, a
37% reduction in C-reactive protein lev-
els, and a roughly 50% decrease in car-
diovascular complications.10The publica-
tion of the JUPITER trial (in November
2008) was much anticipated since the
announcement of the trial’s premature dis-
continuation inMarch 2008,19,20 at ameet-
ing of the American College of Cardiol-
ogy, following the presentation of the
disappointing results of the ENHANCE
(Ezetimibe and Simvastatin in Hypercho-
lesterolemia Enhances Atherosclerosis
Regression) trial.9 Similarly to ezetimibe
(tested in the ENHANCE trial), rosuva-
statin was already the subject of aggres-
sive marketing despite the absence of evi-
dence that its use actually decreased CHD
complications. Indeed, disregarding open-
label studies such as ASTEROID (A Study
See also pages 1007,
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Author Affiliations: Laboratoire
Cœur and Nutrition, Faculty of
Medicine, Universite´ Joseph
Fourier and Centre National de
la Recherche Scientifique,
Grenoble, France (Dr de Lorgeril
and Ms Salen); Harvard Medical
School, Boston, Massachusetts
(Dr Abramson); Department of
Obstetrics and Gynaecology,
Laval University, Quebec City,
Quebec, Canada (Dr Dodin);
Department of Clinical Sciences,
Institute of Natural Medicine,




(Dr Kostucki); Open Research






France (Dr Pavy); and
Cardiology Department,
Clinique de Genolier, Genolier,
Switzerland (Dr Rabaeus).
(REPRINTED) ARCH INTERN MED/VOL 170 (NO. 12), JUNE 28, 2010 WWW.ARCHINTERNMED.COM
1032
©2010 American Medical Association. All rights reserved.
Downloaded From: http://archinte.jamanetwork.com/ on 07/30/2013
to Evaluate the Effect of Rosuvastatin on Intravascular
Ultrasound-Derived Coronary Atheroma Burden),21 3
trials with rosuvastatin (CORONA [Controlled Rosu-
vastatinMultinational Trial in Heart Failure],1GISSI-HF
[Gruppo Italiano per lo Studio della Sopravvivenza
nell’InfartoMiocardio–Heart Failure],3 and AURORA [A
Study to Evaluate the Use of Rosuvastatin in Subjects on
Regular Haemodialysis: An Assessment of Survival and
Cardiovascular Events]5) had been conducted, and all had
failed to provide evidence that rosuvastatin therapy re-
duces CHD complications. The failure of rosuvastatin to
show a significant protective effect was also true for pa-
tients with establishedCHD, becausemost patients in the
CORONA and GISSI-HF trials were survivors of a pre-
vious myocardial infarction.
METHODOLOGICAL PROBLEMS
IN THE JUPITER TRIAL
The JUPITER trial was prematurely terminated. Although
having prespecified early stopping rules is a well-accepted
feature of clinical trials, it is critical that the rules truly be
prespecified. In the case of the JUPITER trial, the prespeci-
fied ruleswere not detailed in the published description of
the study protocol.22 Indeed, we still do not know which
end point was used to define them, or which level of ben-
efits—unexpectedon thebasis of the apriori calculatedhy-
pothesis22—was required to justify early termination.Also,
it was recently shown that truncated trials are associated
withgreatereffect sizes than trials that arenot stoppedearly,
and this effect is independent of the presence of statistical
stopping rules.23 In defending the decision to end the trial
early, the JUPITER investigators stated that the decision
was notmade by them but bymembers of an independent
safety-monitoring board.24 However, the chairman of this
board—an investigator of theClinical Trial ServiceUnit of
Oxford University, Oxford, England—has been, and still
is, involved in many other industry-sponsored lipid-
lowering trials, raising issues of conflict of interest.25,26
Fueling concern about the termination of the study is
that the data are not consistent with a large difference be-
tween treatment and placebo. The primary end point
(Table, line 1) is a composite of cardiovascular compli-
cations, someofwhich—suchas revascularization andhos-
pital admission—are of less relevance because they are not
complications butmedical decisions. Taking only the hard
end points of fatal and nonfatal myocardial infarction and
stroke (Table, line 8)—the end points that are less open
to bias andmanipulation—the trial was stopped after only
240 events. Furthermore, there was no difference in the
incidence of serious adverse events (total hospitaliza-
tions, prolongations of hospitalizations, cancer, and per-
manent disability) between the 2 groups.
Moreover, a close examination of the all-causemortal-
ity curves (Figure 1D in the first JUPITER article10) shows
that the curveswere actually convergingwhen the trialwas
ended, suggesting that the borderline significant differ-
ence between groups may have disappeared in case of a
slightly longer follow-up. Strangely, in a subsequent ar-
ticle27 that was apparently written to defuse the contro-
versy, the all-causemortality curveswere truncated so that
the previous converging portionwas no longer displayed.
CLINICAL AND EPIDEMIOLOGICAL
INCONSISTENCIES IN THE JUPITER TRIAL
In any trial, the consistency of clinical data must be ex-
amined to determine whethermethodological flaws have
increased the risk of bias. For instance, in cardiology, com-
parison of the rate of hard end points—fatal and nonfa-
talmyocardial infarction and stroke,which representmost
cardiovascular complications in any population—to those
expected from a comparable population, at least in the
placebo group, provides such a check on methodology.
At first glance (Table), the difference between the 2
groups in terms of hard end points seems impressive (157
vs 83 for placebo and rosuvastatin, respectively). But are
these differences plausible? Although an “unequivocal re-
duction in cardiovascular mortality” was announced in
March2008 as themain justification for the premature trial
termination,19,20 the absence of cardiovascular mortality
data in the published article is striking.Onemay infer from
the Table—although not indicated in the text—that the
total number of fatal myocardial infarctions was 9 in the
rosuvastatin group (the difference between 31 “anymyo-
cardial infarctions” and 22 “nonfatal myocardial infarc-
tions”) and 6 (68−62) in the placebo group. Similar cal-
culations for fatal stroke (the difference between “any
stroke” and “nonfatal stroke”) show 3 (33−30) in the ro-
suvastatin group and 6 (64−58) in the placebo group.
Cardiovascular mortality (fatal stroke plus fatal myo-
cardial infarction) would therefore be identical in both
groups (12 vs 12). Such a lack of effect on cardiovascu-
lar mortality associated with a strong effect on nonfatal
complications strongly suggests a bias in the data set and
should have led to the continuation of the trial rather than
to its premature ending. Other inconsistencies add to the
confusion.
First, the ratio of fatal myocardial infarction (9 for ro-
suvastatin and 6 for placebo) to nonfatal myocardial in-
farction (22 and 62) is incredibly low, especially in the pla-
cebo group.Mortality from acutemyocardial infarction is
a very important issue in cardiology. The data would sug-
gest that the hearts of the JUPITER patients were unex-
pectedly—and inexplicably—highly resistant to acute is-
chemia and infarction. The worst consequence of low








Primary end pointb 142 251
Nonfatal myocardial infarction 22 62
Any myocardial infarction 31 68
Nonfatal stroke 30 58
Any stroke 33 64
Arterial revascularization 71 131
Hospitalization for unstable angina 16 27
Myocardial infarction, stroke, or confirmed
deaths from cardiovascular causes
83 157
Death from any cause on known date 190 235
aAdapted from Ridker et al.10
bA combination of myocardial infarction, stroke, arterial revascularization,
hospitalization for unstable angina, or death from cardiovascular causes.
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myocardial resistance to ischemia is death, often sudden
cardiac death (SCD).Myocardial infarction–related death,
the “case-fatality rate” in epidemiological reports, is usu-
ally very high and is known, thanks to the World Health
Organization’sMONICA study, inmany populationswith
very different risks.28Out of 100 patientswho have amyo-
cardial infarction, an average of 50 die immediately—
usually out of hospital—or within the 3 to 4 weeks that
follow, and almost never fewer than 40 out of 100, even
in populations with low cardiovascular mortality, for ex-
ample in Japan and around theMediterranean sea.28 In the
JUPITER trial, the case-fatality rate in the placebo group
was incredibly low: 8.8%, a clinical inconsistency that sug-
gests a major flaw in the study. Moreover, the case-
fatality rate in the rosuvastatin group was 29%. This rate
was significantly different from that in the placebo group
(Fisher exact test,P=.01) andmore consistentwith (though
still lower than) the range reported in theMONICAstudy.28
Another dilemma is raised by this figure as it would im-
ply that the use of rosuvastatin tripled the case-fatality rate.
This figure is not credible.
Second, otherways of calculating cardiovascularmor-
tality in the JUPITER trial could be used. For instance,
Chan et al29 used the combined end point “myocardial
infarctionstrokeconfirmed death from cardiovascu-
lar causes” (line 8 of the Table), from which they re-
moved nonfatal myocardial infarction (line 2) and non-
fatal stroke (line 4). They calculated that the numbers of
deaths from cardiovascular causes were 31 and 37 in the
rosuvastatin and placebo groups, respectively, not a sig-
nificant difference. Because the total number of fatalmyo-
cardial infarction and stroke was 12 in both groups, it
would mean that there were 19 and 25 cardiovascular
deaths thatwerenotdue tomyocardial infarctionor stroke.
The question raised is obvious:What are the causes of
these somany“other” cardiovasculardeaths? In theMarch
5, 2009, issue of the New England Journal of Medicine,
Ridker andGlynn24 explain that the calculations by Chan
and colleagues are incorrect “because they do not ac-
count for deaths from vascular causes, such as aneu-
rysm rupture.” Would this mean that in the same pe-
riod of time there were 6 fatal infarctions and 25 fatal
aneurysm ruptures in the placebo group? This is highly
unlikely and still does not explain why the calculations
made by Chan and coauthors are incorrect. Even Ridker
and Glynn write that the number of confirmed deaths
from cardiovascular causes was 35 in the rosuvastatin
group and 43 in the placebo group (no significant dif-
ference), based on “very strict end point classification cri-
teria” that are not clearly described, and surprisingly do
not mention SCD.
Sudden cardiac death actually is the simplest andmost
reliable diagnosis in cardiology because, contrary tomyo-
cardial infarction, there is no need for biologic and/or elec-
trocardiographic criteria. It is defined as a death occur-
ring within 1 hour after the first symptoms of heart
attack—or as an unwitnessed death.30 It is therefore very
surprising that no SCD is reported in the JUPITER trial
because SCDusually represents about 65% to 70%of total
cardiac mortality.31 As previously underlined,32 the way
SCD is reported—or not reported—may be a good indi-
cator of the quality of the methods used in a trial.
Noneof these clinically inconsistent numbers has been
explained in the different JUPITER articles.10,27,33 Al-
though it is quite unusual that the burden of calculating
cardiovascularmortality is placedon the readers, allmeth-
ods used, however, lead to the same conclusion: there is
no significant difference in cardiovascular mortality be-
tween the 2 groups in the JUPITER trial. Moreover, car-
diovascular mortality in the JUPITER trial appears to be
unexpectedly low compared with total mortality—
between 5 and 18%, depending on the means of calcu-
lation—whereas the expected ratewould have been close
to 40% in a non-Japanese and non-Mediterranean popu-
lation.28,34 These mortality data are not epidemiologi-
cally consistent, and the early terminationof the JUPITER
trial likely was, at least partly, responsible for that lack
of consistency.
Therefore, the JUPITER data set appears biased. Three
other trials1,3,5 involving rosuvastatin therapy in high-
risk patients did not show any protection. The authors
of the JUPITER study fail to comment on these negative
trials but go on to report secondary end point and sub-
group analyses that appear to support the efficacy (and
safety) of rosuvastatin therapy.35-38 For example, an en-
tire article was devoted to reporting a significant benefit
in 1 secondary end point, reduction of venous throm-
boembolisms,35 whereas the significant increase in new
diagnoses of diabetes among patients taking rosuva-
statin—a no less important secondary outcome—was rel-
egated to a short comment.10 Similarly, secondary analy-
ses of subgroups—women,36 patients with moderate
chronic kidney disease,37 or persons 70 years or older38—
are subject to all the limitations of the main data set.
THE SPONSOR’S ROLE AND CONFLICTS
OF INTEREST IN THE JUPITER TRIAL
The JUPITER trial involved multiple conflicts of inter-
est. It was conducted by a sponsor with obvious com-
mercial interests. Nine of 14 authors of the JUPITER ar-
ticle10 have financial ties to the sponsor. The principal
investigator has a personal conflict of interest as a co-
holder of the patent for the C-reactive protein test.
The sponsor’s pervasive role is clearly described in the
second paragraph of the “Methods” section of the re-
port: “the sponsor collected the trial data and moni-
tored the study sites.”10 It means that the sponsor’s own
investigators controlled andmanaged the raw data. This
does not mean that raw data have been modified before
being transmitted to statisticians, but it does increase the
chance of bias seeping into the data set, as the misrep-
resentation of data about rofecoxib,39,40 gabapentin,41 and
ENHANCE9,42-44 have shown.
In conclusion, the results of the JUPITER trial are clini-
cally inconsistent and therefore should not change medi-
cal practice or clinical guidelines. The results of the
JUPITER trial support concerns that commercially spon-
soredclinical trials are at riskofpoorquality andbias.Docu-
mentation of the failure of the JUPITER trial to demon-
strate a protective effect of rosuvastatin is all the more
important as it occurred in the context of the failure ofmore
than 12 other cholesterol-lowering trials published in re-
cent years and in various clinical settings.1-9,45-48 None of
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these trials provided significant evidence of protection
against CHD complications—especially fatal complica-
tions—by cholesterol lowering. Two other cholesterol-
lowering studies were either not published49 or abruptly
halted50 because of lack of effect. These failures strongly
suggest that the presumedpreventive effects of cholesterol-
lowering drugs have been considerably exaggerated.32,51
Clearly, the time has come for a critical reappraisal of
cholesterol-lowering and statin treatments for the preven-
tion of CHD complications. The emphasis on pharmaceu-
ticals for thepreventionofCHDdiverts individual andpub-
lic health attention away from the proven efficacy of
adopting a healthy lifestyle, including regular physical ac-
tivity, not smoking, and a Mediterranean-style diet.52,53
Accepted for Publication: April 20, 2010.
Correspondence: Michel de Lorgeril, MD, Laboratoire
Cœur and Nutrition, Faculte´ de Me´decine, TIMC-
IMAG, Universite´ Joseph Fourier and Centre National
de la Recherche Scientifique, UMR 5525, Domaine de la
Merci, 38706 La Tronche, France (michel.delorgeril
@ujf-grenoble.fr).
Author Contributions: Study concept and design: de Lor-
geril and Rabaeus. Acquisition of data: Hamazaki. Analy-
sis and interpretation of data: de Lorgeril, Salen, Abram-
son, Dodin, Hamazaki, Kostucki, Okuyama, and Pavy.
Drafting of the manuscript: de Lorgeril and Rabaeus.Criti-
cal revision of the manuscript for important intellectual con-
tent:de Lorgeril, Salen, Abramson,Dodin,Hamazaki, Kos-
tucki, Okuyama, Pavy, and Rabaeus. Statistical analysis:
de Lorgeril and Abramson. Administrative, technical, and
material support: Abramson. Study supervision: Kostucki
and Rabaeus.
Financial Disclosure:Dr Abramson has served as an ex-
pert for plaintiffs’ attorneys in litigation involving the phar-
maceutical industry (not involving rosuvastatin), as an
unpaid consultant to the Federal Bureau of Investiga-
tion and the Department of Justice in investigations in-
volving the pharmaceutical industry, and as a consul-
tant to Wells Fargo Insurance Services.
Disclaimer: The opinions and analyses expressed by the
authors do not necessarily reflect the opinions of the au-
thors’ affiliated institutions.
REFERENCES
1. Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group. Rosuvastatin in older
patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-2261.
2. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of
torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;
357(21):2109-2122.
3. Tavazzi L, Maggioni AP, Marchioli R, et al; GISSI-HF Investigators. Effect of rosu-
vastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized,
double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-1239.
4. Rossebø AB, Pedersen TR, Boman K, et al; SEAS Investigators. Intensive lipid
lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;
359(13):1343-1356.
5. Fellström BC, Jardine AG, Schmieder ME, et al; AURORA Study Group. Rosu-
vastatin and cardiovascular events in patients undergoing hemodialysis. N Engl
J Med. 2009;360(14):1395-1407.
6. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Inves-
tigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing
hemodialysis. N Engl J Med. 2005;353(3):238-248.
7. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorva-
statin in the prevention of cardiovascular end points in subjects with type 2 dia-
betes: the Atorvastatin Study for Prevention of Coronary Heart Disease End-
points in Non–Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care. 2006;
29(7):1478-1485.
8. Cowell SJ, Newby DE, Prescott RJ, et al; Scottish Aortic Stenosis and Lipid Low-
ering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial
of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;
352(23):2389-2397.
9. Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with
or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358
(14):1431-1443.
10. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin
to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008;359(21):2195-2207.
11. Donner-Banzhoff N, Sönnichsen A. Statins and primary prevention of cardiovas-
cular events. BMJ. 2008;337:a2576.
12. Nissen SE. The Jupiter trial: key findings, controversies and implications. Curr
Cardiol Rep. 2009;11(2):81-82.
13. Vaccarino V, Bremner JD, Kelley ME. JUPITER: a few words of caution. Circ Car-
diovasc Qual Outcomes. 2009;2(3):286-288.
14. Hlatky MA. Expanding the orbit of primary prevention: moving beyond JUPITER.
N Engl J Med. 2008;359(21):2280-2282.
15. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new pa-
tients for statin therapy using data from the 1999–2004 National Health and Nu-
trition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2(1):41-48.
16. Wood S. Eyes trained on JUPITER: cardiologists seek details to understand how
statin use may expand. Medscape Web site. http://www.medscape.com/viewarticle
/583040. Accessed November 6, 2008.
17. Normal cholesterol? you may still be at risk. CardioSmart Web site. http://www
.cardiosmart.org/News/Default.aspx?id=2238. Accessed November 9, 2008.
18. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients
with stable ischemic heart disease. Arch Intern Med. 2005;165(2):221-226.
19. O’Riordan M. Crestor outcomes study JUPITER closes early due to unequivocal
evidence of benefit. theheart.org Web site. http://www.theheart.org/article/852735
.do. Accessed March 31, 2008.
20. O’Riordan M. JUPITER halted: rosuvastatin significantly reduces cardiovascular
morbidity and mortality. Medscape Web site. http://medscapemobile.com
/viewarticle/572270. Accessed April 1, 2008.
21. Ballantyne CM, Raichlen JS, Nicholls SJ, et al; ASTEROID Investigators. Effect
of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coro-
nary angiography: a study to evaluate the effect of rosuvastatin on intravascular
ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458-
2466.
22. Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of car-
diovascular disease among patients with low levels of low-density lipoprotein
cholesterol and elevated high-sensitivity C-reactive protein: rationale and de-
sign of the JUPITER trial. Circulation. 2003;108(19):2292-2297.
23. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stopping random-
ized trials early for benefit and estimation of treatment effects: systematic re-
view and meta-regression analysis. JAMA. 2010;303(12):1180-1187.
24. Ridker PM, Glynn RJ. Rosuvastatin in patients with elevated C-reactive protein
[reply]. N Engl J Med. 2009;360(10):1041-1042.
25. Mueller PS, Montori VM, Bassler D, Koenig BA, Guyatt GH. Ethical issues in stop-
ping randomized trials early because of apparent benefit. Ann Intern Med. 2007;
146(12):878-881.
26. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early
for benefit: a systematic review. JAMA. 2005;294(17):2203-2209.
27. Ridker PM. The JUPITER trial: results, controversies and implications for prevention.
Circ Cardiovasc Qual Outcomes. 2009;2(3):279-285.
28. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel
P. Contribution of trends in survival and coronary-event rates to changes in coro-
nary heart disease mortality: 10-year results from 37 WHO MONICA project popu-
lations: monitoring trends and determinants in cardiovascular disease. Lancet.
1999;353(9164):1547-1557.
29. Chan PS, Nallamothu BK, Hayward RA. Rosuvastatin in patients with elevated
C-reactive protein [letter]. N Engl J Med. 2009;360(10):1039.
30. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98(21):2334-2351.
31. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United
States, 1989 to 1998. Circulation. 2001;104(18):2158-2163.
32. de Lorgeril M, Salen P. Cholesterol lowering and mortality: time for a new paradigm?
Nutr Metab Cardiovasc Dis. 2006;16(6):387-390.
33. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Trial Study Group. Reduc-
tion in C-reactive protein and LDL cholesterol and cardiovascular event rates af-
ter initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet.
2009;373(9670):1175-1182.
34. de Lorgeril M, Salen P, Paillard F, Laporte F, Boucher F, de Leiris J. Mediterra-
nean diet and the French paradox: two distinct biogeographic concepts for one
consolidated scientific theory on the role of nutrition in coronary heart disease.
Cardiovasc Res. 2002;54(3):503-515.
35. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the
prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851-1861.
36. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the
(REPRINTED) ARCH INTERN MED/VOL 170 (NO. 12), JUNE 28, 2010 WWW.ARCHINTERNMED.COM
1035
©2010 American Medical Association. All rights reserved.
Downloaded From: http://archinte.jamanetwork.com/ on 07/30/2013
primary prevention of cardiovascular events in women with elevated high-
sensitivity C-reactive protein or dyslipidemia: results from the Justification for
the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin
( JUPITER) and meta-analysis of women from primary prevention trials. Circulation.
2010;121(9):1069-1077.
37. Ridker PM, Macfadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among
men and women with moderate chronic kidney disease and elevated high-sensi-
tivity C-reactive protein: a secondary analysis from the JUPITER ( Justification for
the Use of Statins in Prevention—an Intervention Trial Evaluating Rosuvastatin)
trial. J Am Coll Cardiol. 2010;55(12):1266-1273.
38. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin
for primary prevention in older persons with elevated C-reactive protein and low
to average low-density lipoprotein cholesterol levels: exploratory analysis of a
randomized trial. Ann Intern Med. 2010;152(8):488-496, W174.
39. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwrit-
ing in publications related to rofecoxib: a case study of industry documents from
rofecoxib litigation. JAMA. 2008;299(15):1800-1812.
40. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alz-
heimer disease or cognitive impairment: a case study based on documents from
rofecoxib litigation. JAMA. 2008;299(15):1813-1817.
41. Landefeld CS, Steinman MA. The Neurontin legacy: marketing through misin-
formation and manipulation. N Engl J Med. 2009;360(2):103-106.
42. Mitka M. Controversies surround heart drug study: questions about Vytorin and
trial sponsors’ conduct. JAMA. 2008;299(8):885-887.
43. Greenland P, Lloyd-Jones D. Critical lessons from ENHANCE trial. JAMA. 2008;
299(8):953-955.
44. O’Riordan M. Congress continues to probe Merck and Schering-Plough: angry emails
highlight ENHANCE controversy. Medscape Web site. http://www.medscape.com
/viewarticle/572392. Accessed April 1, 2008.
45. Asselbergs FW, Diercks GFH, Hillege HL, et al; Prevention of Renal and Vascular
Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effect of fosin-
opril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Circulation. 2004;110(18):2809-2816.
46. Pedersen TR, Faergeman O, Kastelein JJ, et al; Incremental Decrease in End Points
Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin
vs. usual-dose simvastatin for secondary prevention after myocardial infarction:
the IDEAL study, a randomized controlled trial. JAMA. 2005;294(19):2437-2445.
47. Bowman L, Armitage J, Bulbulia R, Parish S, Collins R; SEARCH Study Collabo-
rative Group. Study of the effectiveness of additional reductions in cholesterol
and homocysteine (SEARCH): characteristics of a randomized trial among 12064
myocardial infarction survivors. Am Heart J. 2007;154(5):815-823, 823.e1-e6.
48. Study of the effectiveness of additional reductions in cholesterol and homocys-
teine (SEARCH). ISRCTN Register Web site. http://www.controlled-trials.com
/ISRCTN74348595/. Accessed December 12, 2007.
49. O’Riordan M. CASHMERE: no IMT effect with atorvastatin over 12 months. the-
heart.org Web site. http://www.theheart.org/article/880873.do. Accessed July 9,
2008.
50. O’Riordan M. ACHIEVE stopped: IMT study with Niacin/Laropiprant halted by Merck
& Co. theheart.org Web site. http://www.theheart.org/article/869153.do. Accessed
May 22, 2008.
51. de Lorgeril M. Disappointing recent cholesterol-lowering drug trials: is it not time
for a full reappraisal of the cholesterol theory? World Rev Nutr Diet. 2009;100:
80-89.
52. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean
diet, traditional risk factors and the rate of cardiovascular complications after myo-
cardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;
99(6):779-785.
53. de Lorgeril M, Salen P, Martin JL, Boucher F, Paillard F, de Leiris J. Wine drinking
and risks of cardiovascular complications after recent acute myocardial infarction.
Circulation. 2002;106(12):1465-1469.
Call for Photographs
The Archives is seeking photographs to be included as
fillers in our journal. We believe that our readers may
be an excellent source of interesting and thoughtful pho-
tographs. If you would like us to consider your photog-
raphy for publication, we invite you to submit your pho-
tograph to our Web-based submission site under the
category Images FromOur Readers at http://manuscripts
.archinternmed.com. Please upload photograph submis-
sions in .jpg or .tif format. Hard copy photographs are
not acceptable. For more information please e-mail
archinternmed@jama-archives.org.
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